Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,276 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07392580 | Intralesional Chemotherapy (IC): Cisplatin + Epinephrine | recruiting | Phase 2 | 20 | University of MiamiOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07561645 |
| A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung(ALPINE 2) |
| not yet recruiting |
| Phase 2 |
| 75 |
| Technische Universität DresdenOTHER |
| 0 |
| Aug 26, 2026 |
| clinicaltrials |
| NCT07700667 | SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 120 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07720726 | Impact of Dysport on PMFF Donor Scar | not yet recruiting | Phase 4 | 50 | Vanderbilt University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07786428 | Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC(DETENTE-1) | not yet recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787156 | Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial(REGENERATE) | not yet recruiting | N/A | 80 | Brigham and Women's HospitalOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787273 | Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 84 | Hefei Cancer Hospital of the Chinese Academy of SciencesNETWORK | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07787338 | SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer | not yet recruiting | Phase 2 | 80 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788222 | Sacituzumab Govitecan and Q901 in Advanced TNBC | not yet recruiting | Phase 2 | 48 | Yonsei UniversityOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT03206060 | Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma | recruiting | Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04510740 | Liver Cancer Registry Platform(JADE) | active not recruiting | — | 1,000 | iOMEDICO AGINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04770896 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab(IMbrave251) | active not recruiting | Phase 3 | 557 | Hoffmann-La RocheINDUSTRY | 28 | Aug 25, 2026 | clinicaltrials |
| NCT04847063 | Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies | recruiting | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05886049 | A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease | recruiting | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06022822 | Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | recruiting | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06067503 | Biomarkers to Detect Endocrine Therapy Resistance | recruiting | Phase 2 | 8 | University of Wisconsin, MadisonOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06958328 | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer(LAP100) | recruiting | Phase 3 | 356 | NRG OncologyOTHER | 2 | Aug 25, 2026 | clinicaltrials |
| NCT07488923 | A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) | recruiting | Phase 1 | 110 | Moonlight Bio, IncINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07654400 | A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer | recruiting | Phase 2 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07689175 | Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma | recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07780968 | Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA(ZOLA) | not yet recruiting | — | 300 | Jazz PharmaceuticalsINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07784855 | Scheduled IV Fluids in the Supportive Management of Patients Undergoing Chemo-radiotherapy for Head and Neck Cancer | not yet recruiting | N/A | 180 | West Virginia UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT00001238 | Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders | recruiting | — | 5,000 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT00453674 | German Adrenocortical Carcinoma Registry | recruiting | — | 1,000 | University of WuerzburgOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT02068794 | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | active not recruiting | Phase 1 / Phase 2 | 34 | Mayo ClinicOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03801876 | Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | active not recruiting | Phase 3 | 300 | NRG OncologyOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05501704 | ETHAN - ET for Male BC | recruiting | Phase 2 | 60 | Jose Pablo LeoneOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05517811 | Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection(TEG) | recruiting | — | 200 | University of Colorado, DenverOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05775159 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | active not recruiting | Phase 2 | 294 | AstraZenecaINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT06586515 | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01) | recruiting | Phase 1 | 630 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT07596212 | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder | not yet recruiting | Phase 1 / Phase 2 | 100 | University of Illinois at ChicagoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07739758 | A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer | recruiting | Phase 3 | 442 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07743190 | A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)(NeoTILs) | recruiting | Phase 2 | 55 | Medical University of South CarolinaOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07780877 | Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer | not yet recruiting | Phase 2 | 85 | Fudan UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781072 | Sintilimab Plus Hypofractionated Radiotherapy Followed by Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 27 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781137 | Analysis of Long-term Outcomes of Endoscopic Resection of Duodenal and Ampullary Mucosal and Submucosal Lesions(DuoP-ER) | recruiting | — | 1,000 | Western Sydney Local Health DistrictOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07781176 | Different Acupoint Stimulation for Postoperative Gastrointestinal Dysfunction in Primary Liver Cancer Patients | not yet recruiting | N/A | 132 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 24, 2026 | clinicaltrials |
| NCT07782632 | Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma | recruiting | — | 467 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 24, 2026 | clinicaltrials |
| NCT01893307 | Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer | active not recruiting | Phase 3 | 440 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02466971 | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | active not recruiting | Phase 3 | 450 | National Cancer Institute (NCI)NIH | 3 | Aug 21, 2026 | clinicaltrials |
| NCT03655002 | IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer | active not recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04360941 | PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer(PAveMenT) | active not recruiting | Phase 1 | 45 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04535401 | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines | active not recruiting | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 26, 2026source: clinicaltrials